



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

5th August 2022

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, For,
Mumbai 400001

Scrip Code: 52481

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza, Bandra Kurla Complex
Bandra East, **Mumbai 400051**

Scrip Code: NATCOPHARM

Dear Sir

Sub: - **Q1 FY23 Financial Results Earnings Call**

The Company will host an Earnings Call with Investors / Analysts at **11.00 a.m. IST on Wednesday 10th August, 2022**, to disseminate Financial Results of the company for the quarter ended on 30th June, 2022. Copy of the same is enclosed for your ready reference.

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO PHARMA

Hosted by Edelweiss Securities



India Equity Research

August 3, 2022

Edelweiss Securities is hosting a conference call with the management of Natco Pharma to discuss the Company's Q1FY23 financial results on Wednesday, August 10, 2022 at 11.00 AM IST.

Mr. Rajeev Nannapaneni, Director & Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President – Crop Health Sciences will represent Natco Pharma on the call.

Details of the conference call are as under:

Time : 11.00AM IST on Wednesday, August 10, 2022

Conference dial-in:		
India	:	Mumbai
		Primary access number
		+ 91 22 6280 1560
		+91 22 7115 8200
USA	:	1 866 746 2133
UK	:	0 808 101 1573
Singapore Toll Free No.	:	800 101 2045
Hong Kong Toll Free No.	:	800 964 448

Call leader Mr. Kunal Randeria

For further information please contact:

Kunal Randeria

Edelweiss Securities Ltd.

Tel.: +91 22 6620 3040

Fax: +91 22 2286 4310

E-mail: kunal.randeria@edelweissfin.com

Express Join with [DiamondPass™](#)